Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025

by Business Wire • 2025/11/04 • 0 Comments

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025

← Ocular Rosacea Underappreciated in Dermatology and Beyond

Healio AI: AI assistant built on trusted medical sources →

Post navigation